With a one year PEG ratio of 0.14, Enzo Biochem Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than just 3.57% of US stocks.
With a year-over-year growth in debt of 685.38%, Enzo Biochem Inc's debt growth rate surpasses 97.11% of about US stocks.
Over the past twelve months, ENZ has reported earnings growth of -2,121.91%, putting it ahead of just 0.86% of US stocks in our set.
Stocks with similar financial metrics, market capitalization, and price volatility to Enzo Biochem Inc are MYGN, JMP, CALM, OFIX, and UFCS.
Enzo Biochem, Inc. ($0.01 Par Value) (ENZ) Company Bio
Enzo Biochem, Inc. engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company was founded in 1976 and is based in New York, New York.
Enzo Biochem ([[ENZ]] -0.6%) partners with Community Pharmacy Enhanced Services Network, to provide COVID-19 testing at 52 of the network’s 155 pharmacies across New York State.The company will provide the full range of services, including reagent manufacturing capabilities, diagnostic instruments, and clinical laboratory services....
Shares of Enzo Biochem Inc. rallied 7.7% in premarket trading on Monday after the company said it received an emergency use authorization from the Food and Drug Administration for its COVID-19 diagnostic test. The regulator issued the EUA on July 7. It has granted emergency authorization to at least 137 diagnostic tests during the COVID-19 pandemic. Enzo's stock is up 8.7% year-to-date. The S&P 500 has declined 1.4% since the start of the year.